Wells Fargo Raises Biogen (BIIB) Price Target to $200 | BIIB Sto

NodeGuardian · 2026-02-23T05:33:37+00:00

Wells Fargo raised its price target for Biogen to $200, maintaining an 'Equal-Weight' rating. This change, by analyst Mohit Bansal, indicates a cautious outlook, with a slight downside from the average target price of $200.49, though GuruFocus suggests potential upside.

NodeGuardian

2026-02-23 05:33:37

Abstract generation in progress

Wells Fargo has increased its price target for Biogen (BIIB) to $200 from $190, while maintaining an ‘Equal-Weight’ rating. This adjustment reflects analyst Mohit Bansal’s revised outlook for the biopharmaceutical company. Biogen, a leader in neurological and rare disease treatments, has an average analyst target price of $200.49, suggesting a slight downside from its current price, but GuruFocus estimates an upside based on its GF Value.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes